A Phase 3 interventional study of Sirolimus and tacrolimus in Renal Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-05-14.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
Drug: Sirolimus · Drug: tacrolimus · Drug: Cyclosporine A
Continued calcineurin inhibitor therapy
Drug: Sirolimus · Drug: tacrolimus · Drug: Cyclosporine A
Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
Nankivell Glomerular Filtration Rate (GFR)
Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function.
Time frame: 52 weeks
First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.
Number of patients who experienced for the first time either biopsy-confirmed acute rejection, graft loss, or death by weeks 52 and 104. Assessed by individual endpoint and as composite endpoint (all combined).
Time frame: 52 and 104 weeks
Patients were recruited worldwide from January 2002 to September 2003.
| Milestone | SRL Conversion in Stable Renal Transplant Recipients | CNI Continuation in Stable Renal Transplant Recipients |
|---|---|---|
| Started | 555 | 275 |
| Completed | 386 | 198 |
| Not completed | 169 | 77 |
| Withdrew: Adverse event | 131 | 43 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Nonmedical event | 5 | 7 |
| Withdrew: Withdrawal by subject | 23 | 10 |
| Withdrew: Protocol violation | 3 | 7 |
| Withdrew: Lack of efficacy | 3 | 6 |
Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function.
| mL/min | SRL Conversion Strata 20.0-40.0 mL/Min | CNI Continuation Strata 20.0-40.0 mL/Min | SRL Conversion Strata >40.0 mL/Min | CNI Continuation Strata >40.0 mL/Min |
|---|---|---|---|---|
| Nankivell Glomerular Filtration Rate (GFR) | 24.56 ± 2.42 | 27.24 ± 3.71 | 59.04 ± 0.89 | 57.73 ± 1.1 |
Number of patients who experienced for the first time either biopsy-confirmed acute rejection, graft loss, or death by weeks 52 and 104. Assessed by individual endpoint and as composite endpoint (all combined).
| patients | SRL Conversion Strata 20.0-40.0 mL/Min | CNI Continuation Strata 20.0-40.0 mL/Min | SRL Conversion Strata >40.0 mL/Min | CNI Continuation Strata >40.0 mL/Min |
|---|---|---|---|---|
| 52 weeks - Acute rejection | 4 | 0 | 8 | 3 |
| 52 weeks - Graft loss | 7 | 3 | 3 | 3 |
| 52 weeks - Death | 3 | 0 | 6 | 1 |
| 52 weeks - Missing | 0 | 0 | 5 | 1 |
| 104 weeks - Acute rejection | 5 | 1 | 27 | 9 |
| 104 weeks - Graft loss | 12 | 9 | 12 | 8 |
| 104 weeks - Death | 7 | 0 | 13 | 3 |
| 104 weeks - Missing | 0 | 2 | 13 | 8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SRL Conversion in Stable Renal Transplant Recipients | — | 81/551 (14.7%) | 545/551 (98.9%) |
| CNI Continuation in Stable Renal Transplant Recipients | — | 45/273 (16.5%) | 264/273 (96.7%) |
| Event | SRL Conversion in Stable Renal Transplant Recipients | CNI Continuation in Stable Renal Transplant Recipients |
|---|---|---|
| PneumoniaRespiratory, thoracic and mediastinal disorders | 57/551 | 11/273 |
| FeverGeneral disorders | 43/551 | 10/273 |
| InfectionGeneral disorders | 40/551 | 8/273 |
| Kidney function abnormalRenal and urinary disorders | 29/551 | 18/273 |
| DiarrheaGastrointestinal disorders | 36/551 | 3/273 |
| Creatinine increasedMetabolism and nutrition disorders | 36/551 | 9/273 |
| Urinary tract infectionRenal and urinary disorders | 33/551 | 12/273 |
| Skin carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/551 | 15/273 |
| GastroenteritisGastrointestinal disorders | 28/551 | 4/273 |
| AnemiaBlood and lymphatic system disorders | 21/551 | 3/273 |
| Event | SRL Conversion in Stable Renal Transplant Recipients | CNI Continuation in Stable Renal Transplant Recipients |
|---|---|---|
| HyperlipemiaMetabolism and nutrition disorders | 317/551 | 83/273 |
| HypercholesteremiaMetabolism and nutrition disorders | 245/551 | 44/273 |
| DiarrheaGastrointestinal disorders | 234/551 | 75/273 |
| AnemiaBlood and lymphatic system disorders | 219/551 | 61/273 |
| Peripheral edemaMetabolism and nutrition disorders | 190/551 | 51/273 |
| InfectionGeneral disorders | 177/551 | 71/273 |
| AlbuminuriaRenal and urinary disorders | 166/551 | 45/273 |
| HypertensionCardiac disorders | 127/551 | 68/273 |
| Urinary Tract InfectionRenal and urinary disorders | 127/551 | 58/273 |
| FeverGeneral disorders | 125/551 | 28/273 |
| Age Continuous(years) | SRL Conversion in Stable Renal Transplant Recipients | CNI Continuation in Stable Renal Transplant Recipients | Total |
|---|---|---|---|
| Median | 45.00 (13.20 to 75.10) | 43.50 (12.80 to 74.00) | 44.50 (12.80 to 75.10) |
| Sex: Female, Male(Participants) | SRL Conversion in Stable Renal Transplant Recipients | CNI Continuation in Stable Renal Transplant Recipients | Total |
|---|---|---|---|
| Female | 170 | 81 | 251.0 |
| Male | 385 | 194 | 579.0 |
No study locations are listed for this record.
The record gives a start of Jan 2002, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →